TST198

TST198 is a radionuclide drug conjugate (RDC) currently in IND-enabling development by Suzhou Transcenta. The agent is designed to target Claudin 18.2 (CLDN18.2), a tight junction protein that is frequently overexpressed in various solid tumors, particularly gastric and gastroesophageal junction cancers (G/GEJC). By conjugating a CLDN18.2-specific targeting moiety to a therapeutic radionuclide, TST198 aims to deliver targeted cytotoxic radiation directly to tumor cells while minimizing damage to healthy tissues. This approach leverages the high specificity of the targeting agent and the potent cell-killing capability of radionuclides to treat advanced malignancies that express the CLDN18.2 antigen.